Testing donated immune cells for advanced CD19 blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 16 and 65 years old
- Your B-cell cancer has returned or is resistant after at least two prior treatment lines
- Your cancer is CD19-positive (it has the CD19 marker)
- You can have pregnancy testing and use effective birth control if applicable
- You can sign consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
This Phase 2 trial studies CD19 “redirected” cells made from your own blood to treat certain high-risk or relapsed B-cell acute lymphoblastic leukemia (B-ALL). It may help by targeting cancer cells that carry a protein called CD19.
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
Hear when a new Blood Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.